Skip to content

Author

K. Sapozhnikov

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Comparative efficacy and safety of prolgolimab and nivolumab in first-line therapy for metastatic or unresectable melanoma: a systematic review, matching-adjusted indirect comparison, and cost-effectiveness analysis

Background . Metastatic and unresectable cutaneous melanoma (MM/uRCM) is an aggressive malignancy associated with high mortality due to its pronounced metastatic potential. Immune checkpoint inhibitors are used to treat MM/uRCM in the Russian Federation. These inhibitors include nivolumab and prolgolimab, which...

I. Utyashev, I. Myslevtsev, O. Mironenko et al. · 0 citations
Open access Aug 2026

Divozilimab in neuromyelitis optica spectrum disorders: Evidence-based consensus of Russian committees of experts and clinical potential

Analysis of divozilimab effectiveness and safety long-term results in BCD-132-6/AQUARELLE study and real-world practice will be important steps toward clarifying and potentially extending patient profiles.

V. Krasnov, Y. V. Vlasov, E. Evdoshenko et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.